(S)-1,4-二硫杂-7-氮杂螺[4.4]壬烷-8-羧酸 | 83552-44-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (S)-1,4-二硫杂-7-氮杂螺[4.4]壬烷-8-羧酸
• 英文名称: 1,4-dithia-7-azaspiro<4.4>nonane-8(S)-carboxylic acid
• 英文别名: 4,4-[ethylenebis(thio)]-L-proline；(8S)-1,4-dithia-7-azoniaspiro[4.4]nonane-8-carboxylate
• CAS: 83552-44-7
• 化学式: C₇H₁₁NO₂S₂
• 分子量: 205.302
• InChiKey: PRRCQQGBVXMEKW-YFKPBYRVSA-N

物化性质

• 沸点：
  427.4±45.0 °C(Predicted)
• 密度：
  1.47±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.7
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  99.9
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (S)-1,4-二硫杂-7-氮杂螺[4.4]壬烷-8-羧酸 在 4-二甲氨基吡啶 、 四丁基氟化铵 、 对甲苯磺酸 、 1-羟基苯并三唑一水物 、 三乙胺 、 N,N-二异丙基乙胺 、 N,N'-二环己基碳二亚胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 、 丙酮 、 乙腈 为溶剂， 反应 63.25h， 生成 螺普利
  参考文献：
  名称：

  Angiotensin-converting enzyme inhibitors. Mercaptan, carboxyalkyl dipeptide, and phosphinic acid inhibitors incorporating 4-substituted prolines

  摘要：

  Analogues of captopril, enalaprilat, and the phosphinic acid [hydroxy(4-phenylbutyl)phosphinyl]acetyl]-L-proline incorporating 4-substituted proline derivatives have been synthesized and evaluated as inhibitors of angiotensin-converting enzyme (ACE) in vitro and in vivo. The 4-substituted prolines, incorporating alkyl, aryl, alkoxy, aryloxy, alkylthio, and arylthio substituents were prepared from derivatives of 4-hydroxy- and 4-ketoproline. In general, analogues of all three classes of inhibitors with hydrophobic substituents on proline were more potent in vitro than the corresponding unsubstituted proline compounds. 4-Substituted analogues of captopril showed greater potency and duration of action than the parent compound as inhibitors of the angiotensin I induced pressor response in normotensive rats. The S-benzoyl derivative of cis-4-(phenylthio)captopril, zofenopril, was found to be one of the most potent compounds of this class and is now being evaluated clinically as an antihypertensive agent. In the phosphinic acid series, the 4-ethylenethioketal and trans-4-cyclohexyl derivatives were found to be the most potent compounds in vitro and in vivo. A prodrug of the latter compound, fosinopril, is also being evaluated in clinical trials.

  DOI：

  10.1021/jm00401a014
• 作为产物：
  描述：

  N-<(phenylmethoxy)carbonyl>-1,4-dithia-7-azaspiro<4.4>nonane-8(S)-carboxylic acid ethyl ester 在 sodium hydroxide 、 氢溴酸 、 溶剂黄146 作用下， 以 甲醇 为溶剂， 反应 20.0h， 生成 (S)-1,4-二硫杂-7-氮杂螺[4.4]壬烷-8-羧酸
  参考文献：
  名称：

  血管紧张素转换酶抑制剂：螺哌普利和相关化合物。

  摘要：

  描述了spirapril（5），spiraprilat（25），其RSS立体异构体及其甘氨酰（18b）和赖氨酰（36、37）类似物的合成。在体内评估这些化合物对血管紧张素转化酶（ACE）的抑制作用，并对选定的化合物评估体外ACE抑制作用（螺哌普利ID50为16微克/千克；螺旋体IC50为0.8 nM，ID50为8微克/千克）。在麻醉的大鼠中，iv酯5和36比依那普利更有效，而二酸25和37在体外比依那普利拉更有效。在清醒的大鼠中，口服剂量为0.03-1 mg / kg和依那普利（0.1-1 mg / kg）的依那普利（2）具有持续的活性。从这项工作中，选择了spirapril作为抗高血压药进行临床评估。

  DOI：

  10.1021/jm00127a033

文献信息

• Phosphonamidate compounds
  申请人：E. R. Squibb & Sons, Inc.

  公开号：US04432971A1

  公开（公告）日：1984-02-21

  Phosphonamidates of the formula ##STR1## wherein X is a substituted or unsubstituted imino or amino acid or ester. These compounds possess angiotensin converting enzyme activity and are thus useful as hypotensive agents.

  式中X为取代或未取代的亚胺基或氨基酸或酯。这些化合物具有血管紧张素转化酶活性，因此可用作降压剂。
• Carboxyalkanoyl and hydroxycarbamoylalkanoyl derivatives of substituted prolines
  申请人：E.R. Squibb & Sons, Inc.

  公开号：EP0049589A1

  公开（公告）日：1982-04-14

  Compounds, compositions and method of alleviating hypertension using a compound of the formula wherein R is hydrogen or lower alkyl; R1 is hydrogen, lower alkyl or phenyl-lower alkyl; R2 is hydrogen, lower alkyl, phenyl lower alkyl or halo substituted lower alkyl; R3 is hydroxy, -NHOH or lower alkoxy; Pr-COOR is a substituted proline of the structures or R4 is halogen, keto, azido, cycloalkyl, phenyl, substituted phenyl, phenyl-lower alkyl, substituted phenyl-lower alkyl, R5 is hydrogen or lower alkyl; Y is oxygen or sulfur; R6 is lower alkyl, phenyl, substituted phenyl, phenyl-lower alkyl, substituted phenyl-lower alkyl, 1- or 2-naphthyl, substituted 1- or 2- naphthyl, biphenyl, or substituted biphenyl; R7 is halogen or -Y-R8; R8 is lower alkyl, phenyl, phenyl-lower alkyl substituted phenyl-lower alkyl, biphenyl, napthyl, or the R8 groups join to complete an unsubstituted 5- or 6- membered ring or such ring wherein one or more carbon atoms are substituted by a lower alkyl or di(lower alkyl) group; R9 is keto, phenyl, 2- or 4-hydroxyphenyl; n is 0 or 1; and salts thereof.

  使用式中化合物缓解高血压的化合物、组合物和方法 其中 R 是氢或低级烷基； R1 是氢、低级烷基或苯基低级烷基 R2 是氢、低级烷基、苯基低级烷基或卤代低级烷基； R3 是羟基、-NHOH 或低级烷氧基； Pr-COOR 是以下结构的取代脯氨酸 或 R4 是卤素、酮、叠氮、环烷基、苯基、取代苯基、苯基低级烷基、取代苯基低级烷基、 R5 是氢或低级烷基 Y 是氧或硫； R6 是低级烷基、苯基、取代苯基、苯基-低级烷基、取代苯基-低级烷基、1-或 2-萘基、取代 1-或 2-萘基、联苯或取代联苯； R7 是卤素或-Y-R8； R8 是低级烷基、苯基、苯基-低级烷基取代的苯基-低级烷基、联苯基、萘基，或 R8 基团连接成未取代的 5 或 6 成员环，或其中一个或多个碳原子被低级烷基或二(低级烷基)基团取代的环； R9 是酮、苯基、2-或 4-羟基苯基； n 为 0 或 1；及其盐类。
• Carboxyalkyl dipeptides, processes for their production and pharmaceutical compositions containing them
  申请人：SCHERING CORPORATION

  公开号：EP0050800A1

  公开（公告）日：1982-05-05

  Disclosed are novel carboxyalkyl dipeptides which are useful as inhibitors of angiotensinconverting enzyme and as antihypertensive agents, having the formula and the pharmaceutically acceptable salts thereof, wherein R and R6 are for example hydroxy, lower alkoxy or arylloweralkoxy; R' is for example hydrogen, alkyl, lower alkoxy or aryloxy; R2 and R are the same or different and are hydrogen or lower alkyl; R3 is for example lower alkyl or phenyl lower alkyl; R4 and R5 are selected from hydrogen, lower alkyl and Z, or R4 and R5 taken together form a group represented by Q, U, V, Y, D or E wherein wherein X' and X2 independent of each other are 0, S or CH2, R8 and R9 independent of each other are lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl having 3 to 8 carbon atoms, hydroxy lower alkyl or -(CH2)nAr, wherein n is 0, 1, 2 or 3 or R8 and R9 taken together form a bridge W, wherein W is a single bond or a methylene bridge or a substituted methylene bridge when at least one of X' and X2 is methylene, or W is an alkylene or substituted alkylene bridge having 2 or 3 carbon atoms; with the proviso that at least one of R4 and R5 is Z; wherein L is O or S. The compounds can be prepared according to known methods such as for example by condensation of an aminoacid XXI with an aminoacid XVII wherein X1, X2 and W are as defined above; wherein G is oxygen, sulfur or CH2;

  本发明公开了可用作血管紧张素转换酶抑制剂和降压药的新型羧烷基二肽，其化学式为 其中 R 和 R6 例如是羟基、低级烷氧基或芳基低级烷氧基；R'例如是氢、烷基、低级烷氧基或芳基氧基；R2 和 R 相同或不同，并且是氢或低级烷基；R3 例如是低级烷基或苯基低级烷基；R4 和 R5 选自氢、低级烷基和 Z，或 R4 和 R5 共同形成由 Q、U、V、Y、D 或 E 代表的基团，其中 其中 X' 和 X2 互不相关，分别为 0、S 或 CH2，R8 和 R9 互不相关，分别为低级烷基、低级烯基、低级炔基、具有 3 至 8 个碳原子的环烷基、羟基低级烷基或-(CH2)nAr，其中 n 为 0、1、其中 W 是单键或亚甲基桥或取代的亚甲基桥（当 X' 和 X2 中至少有一个是亚甲基时），或 W 是具有 2 或 3 个碳原子的亚烷基或取代的亚烷基桥；但 R4 和 R5 中至少有一个是 Z； 这些化合物可根据已知方法制备，例如通过氨基酸 XXI 与氨基酸 XVII 缩合 其中 X1、X2 和 W 如上定义； 其中 G 为氧、硫或 CH2；
• Carboxyalkyl amino acid derivatives of various substituted prolines
  申请人：E.R. Squibb & Sons, Inc.

  公开号：EP0052991A1

  公开（公告）日：1982-06-02

  Carboxyalkyl dipeptides of the formula wherein R4 is a 3-, 4-, 5-, or 4,4-substituted proline are disclosed. These compounds are useful as hypotensive agents due to their angiotensin converting enzyme inhibition activity.

  式中的羧烷基二肽 其中 R4 是 3-、4-、5- 或 4,4 取代的脯氨酸。这些化合物具有血管紧张素转换酶抑制活性，可用作降血压药。
• J. Med. Chem. 1988, 31, 1148-1160
  作者：

  DOI：——

  日期：——